查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1925212

環糊精市場（按產品類型、給藥途徑、治療領域和應用分類）－全球預測（2026-2032 年）

Cyclodextrin in Pharma Market by Product Type, Route Of Administration, Therapeutic Area, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，醫藥環糊精市場規模為 13.8 億美元，預計到 2026 年將成長至 15 億美元，預計到 2032 年將達到 22 億美元，複合年成長率為 6.86%。

主要市場統計數據
基準年 2025 13.8億美元
預計年份：2026年 15億美元
預測年份：2032年 22億美元
複合年成長率 (%) 6.86%

為環糊精在現代治療製劑開發、監管管道和臨床應用中的應用奠定基礎

環糊精已從最初的輔料發展成為現代藥物研發的關鍵製劑平台，在提高藥物溶解度、標靶遞送和改善藥物穩定性方面發揮著重要作用。本文全面說明了環糊精應用的理化基礎，重點在於分子包合物的形成、各種BETA-和γ-同系物的安全性，以及不斷擴展的修飾衍生物及其潛在應用。我們闡述如何將這些特性轉化為實用的製劑工具，從而提高傳統上難以處理的原料藥（API）的臨床生物利用度，並改善患者的用藥體驗。

衍生物化學、監管演變和遞送技術的創新如何重塑藥物研發管線中輔料的選擇和開發策略？

環糊精領域正經歷變革性的轉變，這主要得益於衍生物化學的進步、監管力度的加強以及藥物遞送設計領域的跨學科創新。當傳統的BETA-環糊精無法滿足溶解度或安全性方面的要求時，羥丙基和磺丁基衍生物等改性環糊精越來越受到青睞，而持續的合成改進正在提升批次間的一致性和功能性能。同時，一些創新公司正在將基於環糊精的策略整合到標靶遞送系統和緩釋系統中，利用包合物來調節釋放動力學並減少藥物在非標靶部位的暴露。

評估2025年美國關稅對藥品輔料採購、供應鏈韌性和合約風險的策略和營運影響

美國將於2025年實施新的關稅，這將在全球醫藥供應鏈中造成複雜的動態變化，並對輔料採購、價格波動和合約風險分配產生實際影響。關稅壓力促使製造商重新評估其供應商多元化策略，並仔細審查總到岸成本，而不僅僅是單位價格。因此，採購部門正在將關稅情境納入供應商選擇標準，而法務部門正在更新主供應協議，以反映關稅轉嫁或減免條款。

分析產品類型、給藥途徑、功能用途和治療領域細分，以使環糊精的選擇符合技術和監管方面的優先事項。

細緻的細分分析揭示了不同產品類型、給藥途徑、應用和治療領域的影響差異，為相關人員提供了優先進行研發活動的參考依據。改質環糊精和天然環糊精之間的產品類型差異會影響製劑策略和監管依據。改質環糊精，例如羥丙基BETA-環糊精、甲基BETA-環糊精和磺丁基醚BETA-環糊精，具有特殊的溶解性和安全性，而天然α-環糊精、BETA-環糊精和γ-環糊精在結構簡單的包合物即可滿足需求時仍然適用。這些化學選擇會引發製程的考量和雜質控制策略，進而影響下游生產和分析工作量。

美洲、歐洲/中東/非洲和亞太地區的地理監管要求、生產能力和採購實踐如何影響環糊精策略和商業化

區域趨勢對採購、監管策略和商業性應用有顯著影響。美洲、歐洲、中東和非洲地區以及亞太地區各自擁有不同的營運和政策環境。在美洲，法規結構強調輔料安全性和品質的充分記錄，採購實踐也日益重視供應商的透明度、可追溯性以及支持無菌藥品供應鏈的能力。此外，在臨床上獲益明確且有充分數據支持的情況下，先進的製劑方法也得到了快速應用。

從產品創新、監管文件、生產規模和策略夥伴關係關係等分析環糊精價值鏈中的競爭對手。

主要企業已觀察到，環糊精領域的競爭優勢源自於化學創新、品質系統、法規支援和供應鏈穩健性等綜合能力。那些將技術差異化的產品系列組合與完善的雜質控制、可擴展的GMP生產以及積極的監管溝通相結合的企業，引領著產業發展。輔料供應商與藥物研發企業之間的合作關係正從純粹的交易關係轉向策略聯盟，供應商通常會提供配方支援、毒理學資料整理和法規文件，以加速新型環糊精衍生物的應用。

協調環糊精基開發專案中的製劑科學、採購彈性和監管準備的可行策略舉措

產業領導者可以透過採取一系列切實可行的措施，協調科學、供應和商業策略，從而獲得顯著收益。首先，應加快製劑科學家、法規官員和採購團隊之間的跨職能協作，以便在輔料選擇時同時考慮性能合規性和採購風險。其次，對於對給藥途徑敏感的產品，應優先考慮供應商合格流程，重點關注原料來源、雜質控制和無菌生產能力，以降低研發過程中的不確定性和潛在的監管詢問。

透過整合專家訪談、監管分析、分析表徵和供應鏈評估的調查方法，產生決策支援見解。

本研究主要透過對配方科學家、採購人員和法規專家的訪談，並輔以對同行評審論文、法規指導文件和製造商技術文件的文獻綜述。研究方法強調三角驗證，將專家訪談的見解與官方法規立場和原始技術規範檢驗交叉驗證，從而確保研究的科學嚴謹性和實用性。此外，本研究也著重於特定製程路線的要求，以及用於表徵包合物、殘留溶劑和潛在雜質的獨特分析方法。

整合決定環糊精在製藥和治療領域成功應用的技術、監管和供應鏈要素。

總之，環糊精在製劑創新和監管控制的交匯點佔據關鍵地位，為解決不同治療領域的溶解度、穩定性和遞送難題提供了切實可行的途徑。改質環糊精和天然環糊精的化學性質之間的相互作用、不同給藥途徑的限制以及特定臨床應用所需的調整，凸顯了採用嚴謹的跨職能方法選擇輔料的重要性。透過協調技術檢驗、監管文件和穩健的採購流程，企業可以釋放環糊精的潛力，實現治療方法差異化並改善患者預後。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 環糊精在製藥業的市場（依產品類型分類）

  • 變性
    • 羥丙基BETA
    • 甲基BETA
    • 磺丁基醚BETA
  • 自然的
    • 阿爾法
    • 測試版
    • 伽瑪

9. 依給藥途徑分類的環糊精藥用市場

  • 鼻內給藥
    • 滴鼻劑
    • 噴
  • 眼科
  • 口服
    • 液體
      • 懸浮液
      • 糖漿
    • 固態劑型
      • 膠囊
      • 粉末
      • 藥片
  • 腸外給藥
    • 肌肉內注射
    • 靜脈注射
  • 外用藥物
    • 奶油
    • 凝膠
    • 軟膏

10. 環糊精在製藥領域的市場（依治療領域分類）

  • 循環系統
    • 抗高血壓藥物
    • 降血脂藥物
  • 中樞神經系統
    • 抗憂鬱劑
    • 神經保護劑
  • 感染疾病
    • 抗生素
    • 抗病毒藥物
  • 腫瘤學
    • 化療藥物
    • 免疫治療藥物

第11章 依應用分類的環糊精在製藥領域的市場

  • 藥物輸送系統
    • 控釋
      • 緩釋
      • 緩釋
    • 精準投放
  • 溶解度提高
  • 穩定性提高
  • 味道掩蓋

12. 各地區環糊精在製藥領域的市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 環糊精在製藥領域的市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國環糊精醫藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國藥用環糊精市場

第17章：中國醫藥環糊精市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Ashland Global Holdings Inc
  • BASF SE
  • Caldic BV
  • Cargill Incorporated
  • Cerbios-Pharma SA
  • CycloChem Technologies Pvt. Ltd.
  • CycloLab Ltd.
  • Daicel Corporation
  • Hebei Tianxu BIoTechnology Co Ltd
  • Hubei Guangji Pharmaceutical Co Ltd
  • Jiangsu Zhiyuan BIoTechnology Co Ltd
  • Kleptose
  • Kuraray Co Ltd
  • Ligand Pharmaceuticals Incorporated
  • Merck KGaA
  • Nihon Shokuhin Kako Co Ltd
  • Roquette Freres
  • Samyang Corporation
  • Shandong Binzhou Zhiyuan BIoTechnology Co Ltd
  • Shandong Tianli Pharmaceutical Co Ltd
  • Shandong Xinda BIoTechnology Co Ltd
  • Shandong Yunzhou BIoTechnology Co Ltd
  • Shijiazhuang Hongwei BIoTechnology Co Ltd
  • Sichuan Kelong Chemical Co Ltd
  • Tokyo Chemical Industry Co., Ltd.
  • Wacker Chemie AG
  • Wuhan Sinobiological Technology Co Ltd
  • Zhejiang Huakang Pharmaceutical Co Ltd
  • Zibo Qianhui Biological Technology Co Ltd
  • Zibo Shuangfeng Chemical Co Ltd
  • Zibo Zhenhua Chemical Co Ltd
Product Code: MRR-F774F6336ADC

The Cyclodextrin in Pharma Market was valued at USD 1.38 billion in 2025 and is projected to grow to USD 1.50 billion in 2026, with a CAGR of 6.86%, reaching USD 2.20 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.38 billion
Estimated Year [2026] USD 1.50 billion
Forecast Year [2032] USD 2.20 billion
CAGR (%) 6.86%

Establishing the foundational rationale for cyclodextrin adoption across formulation development, regulatory pathways and clinical translation in modern therapeutics

Cyclodextrins have evolved from niche excipients to critical formulation enablers across modern pharmaceutical development, underpinning advances in solubility enhancement, targeted delivery and stability improvement. This introduction synthesizes the physicochemical rationale for cyclodextrin use, emphasizing molecular inclusion complexation, safety profiles across various beta and gamma homologues, and the expanding portfolio of modified derivatives that broaden application possibilities. It maps how these attributes translate into practical formulation levers that enable previously intractable APIs to achieve clinically viable bioavailability and acceptable patient experience.

The narrative begins by framing cyclodextrins within the lifecycle of drug development, from preformulation screening through late-stage manufacturing. It then addresses the interplay between formulation performance and regulatory expectations, noting how excipient provenance, impurity controls and sterilization considerations influence selection across parenteral, ophthalmic and other sensitive administration routes. Finally, the introduction sets out the analytical perspective taken in this report: pragmatic, scientifically grounded, and oriented toward decision-relevant implications for formulation scientists, regulatory leads and commercial strategists. By establishing this baseline, readers are prepared to interpret subsequent sections that explore market dynamics, segmentation nuances and regional policy impacts.

How derivative chemistry, regulatory evolution, and delivery innovation are reshaping excipient selection and development strategies across pharmaceutical pipelines

The cyclodextrin landscape is undergoing transformative shifts driven by advances in derivative chemistry, heightened regulatory scrutiny and cross-disciplinary innovation in drug delivery design. Modified cyclodextrins such as hydroxypropyl and sulfobutyl derivatives are increasingly preferred when conventional beta cyclodextrins do not meet solubility or safety constraints, and ongoing synthetic refinements are enhancing batch consistency and functional performance. Concurrently, innovators are integrating cyclodextrin-based strategies into targeted delivery constructs and controlled-release systems, leveraging inclusion complexation to modulate release kinetics and reduce off-target exposure.

Regulatory pathways are evolving in parallel, with agencies placing greater emphasis on excipient characterization, impurity profiling and clinical justification for novel excipient use. This regulatory tightening is accelerating demand for well-documented safety packages and harmonized quality standards for both natural and modified cyclodextrin variants. Moreover, the industry is witnessing a shift in clinical formulation priorities: there is higher tolerance for advanced excipients when they demonstrably reduce toxicities, enable less invasive routes of administration, or materially improve patient adherence. Together, these forces are reshaping R&D investment patterns, supplier relationships and the types of technical dossiers now expected by regulators and contract manufacturers alike.

Assessing the strategic and operational ramifications of United States tariff measures implemented in 2025 on pharmaceutical excipient sourcing, supply chain resilience and contractual risk

The imposition of new tariffs in 2025 by the United States introduced a compounding factor for global pharmaceutical supply chains that has practical implications for excipient sourcing, pricing dynamics and contractual risk allocation. Tariff pressures have prompted manufacturers to reassess supplier diversification and to scrutinize total landed cost rather than unit price alone. As a result, procurement teams are integrating customs duty scenarios into supplier qualification criteria, and legal teams are updating master supply agreements to reflect potential duty pass-through or mitigationclauses.

Operational responses to tariff-induced disruption include nearshoring certain production steps, qualifying secondary suppliers in tariff-exempt jurisdictions, and adjusting inventory policies to preserve clinical supply continuity. Formulation groups are also re-evaluating backward integration options for key excipients where strategic control reduces exposure to cross-border policy volatility. Importantly, these adaptations are not isolated; they have cascading effects on development timelines, CMO selection, and capital allocation for manufacturing assets. In aggregation, the tariff environment of 2025 has intensified focus on supply chain resilience planning, regulatory harmonization for excipient acceptance, and the need for closer collaboration between commercial, manufacturing and regulatory teams to keep development programs on schedule.

Dissecting product-type, administration route, functional application, and therapeutic-area segmentation to align cyclodextrin selection with technical and regulatory priorities

A nuanced segmentation analysis reveals distinct implications across product types, administration routes, applications and therapeutic areas that stakeholders must account for when prioritizing development activities. Product-type distinctions between modified and natural cyclodextrins influence both formulation strategy and regulatory substantiation: modified variants such as hydroxypropyl beta, methyl beta and sulfobutyl ether beta offer tailored solubility and safety profiles, while natural alpha, beta and gamma cyclodextrins retain relevance where simpler inclusion complexation suffices. These chemical choices cascade into processing considerations and impurity control strategies that affect downstream manufacturing and analytical burden.

Route-of-administration segmentation underscores how performance requirements diverge by clinical intent. Nasal applications require formulations compatible with drops and sprays that balance residence time and mucosal tolerability; ophthalmic use is narrowly focused on drop formulations demanding stringent sterility and ocular tolerance; oral delivery spans liquid and solid presentations, where liquids include suspensions and syrups and solids encompass capsules, powders and tablets with differing excipient interactions; parenteral routes, specified as intramuscular and intravenous, impose the highest sterility and impurity standards; and topical preparations, delivered as creams, gels and ointments, emphasize local tolerance and vehicle compatibility. Application-driven segmentation further clarifies development priorities: when cyclodextrins are leveraged for drug delivery systems the focus shifts to controlled and targeted delivery architectures, with controlled-release programs evaluating both extended and sustained release strategies; when the priority is solubility enhancement or stability improvement the chief concerns are complexation efficiency and degradation pathways; and when taste masking is central to patient acceptance, sensory testing and excipient selection become predominant.

Therapeutic-area segmentation links formulation imperatives to clinical endpoints and safety tolerances. Cardiovascular applications gravitate toward antihypertensive and lipid lowering agents where systemic exposure and long-term safety are paramount. Central nervous system programs, including antidepressants and neuroprotective agents, require consideration of blood-brain barrier permeability and excipient influence on CNS pharmacokinetics. Infectious disease workstreams that involve antibiotic and antiviral agents can prioritize high-concentration aqueous formulations or targeted delivery to infected tissues, while oncology preparations-spanning chemotherapeutic and immunotherapy agents-must reconcile potent APIs with excipient-mediated modulation of toxicity and delivery to tumor microenvironments. Understanding these intersecting segmentation layers enables teams to align formulation pathways, analytical strategies and clinical development plans with both scientific feasibility and regulatory expectations.

How geographic regulatory expectations, manufacturing capabilities, and procurement practices across the Americas, Europe Middle East & Africa, and Asia-Pacific shape cyclodextrin strategy and commercialization

Regional dynamics exert a significant influence on sourcing, regulatory strategy and commercial adoption, with the Americas, Europe Middle East & Africa, and Asia-Pacific each presenting distinct operational and policy landscapes. In the Americas, regulatory frameworks emphasize well-documented excipient safety and quality, and procurement practices increasingly favor supplier transparency, traceability and the ability to support sterile pharmaceutical supply chains. This region also shows rapid adoption of advanced formulation approaches when clinical benefits are clear and supported by robust data packages.

Within Europe, the Middle East & Africa, stakeholders contend with a wide range of regulatory sophistication and market access pathways. European regulatory agencies have stringent excipient characterization expectations, which encourages centralized dossiers and harmonized quality standards, while markets within the Middle East and Africa may present varied acceptance criteria, necessitating adaptive regulatory strategies and flexible commercial models. In contrast, the Asia-Pacific region is characterized by both manufacturing scale and active innovation, with many suppliers offering a broad array of modified cyclodextrin chemistries. Regional policy priorities in Asia-Pacific include local manufacturing incentives and an emphasis on export competitiveness, which can create advantages for companies able to align supply strategies with local regulatory and industrial policies. Cross-regionally, companies are responding by tailoring supply chain architectures, regulatory submissions and commercial engagement to the idiosyncrasies of each geographic cluster, thereby optimizing access to clinical and commercial opportunities while mitigating policy and logistical risk.

Examining how product innovation, regulatory documentation, manufacturing scale, and strategic partnerships differentiate companies competing in the cyclodextrin value chain

Key company insights reveal that competitive differentiation in the cyclodextrin space derives from integrated capabilities across chemistry innovation, quality systems, regulatory support and supply-chain robustness. Leading organizations are those that pair technically differentiated product portfolios with documented impurity control, scalable GMP manufacturing and proactive regulatory engagement. Alliances between excipient suppliers and pharmaceutical developers are increasingly strategic rather than transactional, with suppliers often providing formulation support, toxicology packages and regulatory-facing documentation to accelerate adoption of novel cyclodextrin derivatives.

Innovation leaders also invest in application-specific performance data, demonstrating how particular cyclodextrin grades perform in ophthalmic, parenteral or oral matrices, and how they interact with API classes relevant to cardiovascular, CNS, infectious disease and oncology programs. Contract manufacturers and finished-dose partners that can accommodate sterile processing and complex analytical requirements for parenteral and ophthalmic applications command strategic importance. Finally, companies that maintain geographically diversified manufacturing footprints and transparent supply chains are better positioned to respond to policy shifts and tariff pressures, providing customers with continuity of supply and the technical support necessary to de-risk development programs.

Actionable strategic initiatives to harmonize formulation science, procurement resilience, and regulatory readiness for cyclodextrin-enabled development programs

Industry leaders can extract tangible benefits by adopting a set of actionable initiatives that align science, supply and commercial strategy. First, accelerate cross-functional alignment between formulation scientists, regulatory leads and procurement teams to ensure excipient selections account for performance, compliance and sourcing risk simultaneously. Second, prioritize supplier qualification pathways that emphasize provenance, impurity control and sterile manufacturing capabilities for sensitive routes of administration, thereby reducing development uncertainty and potential regulatory queries.

Third, invest in targeted safety and application data for preferred cyclodextrin grades to build defensible dossiers that facilitate regulatory acceptance across diverse jurisdictions. Fourth, diversify sourcing strategies to include geographically distributed suppliers and to evaluate nearshoring or dual-sourcing where tariffs, logistics or geopolitical risk could threaten continuity. Fifth, embed scenario planning for policy shifts into procurement and development roadmaps so that duty impacts, customs delays or regulatory divergences can be anticipated and mitigated. By implementing these measures, organizations can reduce technical risk, shorten time-to-clinic for challenging APIs, and create more resilient supply chains that align with strategic growth priorities.

Methodological framework integrating expert interviews, regulatory analysis, analytical characterization, and supply-chain assessment to produce decision-ready insights

This research synthesizes primary interviews with formulation scientists, procurement leaders and regulatory specialists, augmented by secondary literature review of peer-reviewed publications, regulatory guidance documents and manufacturer technical dossiers. The approach prioritizes triangulation: insights derived from expert interviews were cross-validated against public regulatory positions and supplier technical specifications to ensure both scientific rigor and practical relevance. Attention was given to route-specific requirements and to the distinct analytical methodologies used to characterize inclusion complexes, residual solvents and potential impurities.

Analytical techniques considered include high-performance chromatography for derivative profiling, mass spectrometry for impurity identification, and in vitro dissolution and permeability assays to evaluate performance across oral, nasal, ophthalmic, parenteral and topical matrices. Regulatory review focused on excipient acceptance criteria, toxicology study expectations and sterility assurance levels applicable to parenteral and ophthalmic applications. Supply-chain assessment incorporated supplier audits, geographic footprint analysis and scenario modeling related to tariff exposure. Throughout, methodological choices emphasized reproducibility of findings, applicability to decision-makers, and clarity in translating technical data into operational recommendations.

Synthesis of technical, regulatory, and supply-chain imperatives that determine successful cyclodextrin deployment across formulation and therapeutic priorities

In conclusion, cyclodextrins occupy a pivotal position at the intersection of formulation innovation and regulatory stewardship, providing pragmatic pathways to address solubility, stability and delivery challenges across therapeutic areas. The interplay between modified and natural cyclodextrin chemistries, the constraints imposed by different routes of administration, and the tailoring required for specific clinical applications underscore the importance of a disciplined, cross-functional approach to excipient selection. When companies align technical validation, regulatory documentation and resilient sourcing, they unlock the potential of cyclodextrins to enable therapeutic differentiation and improve patient outcomes.

Looking forward, success will hinge on the ability to generate application-specific performance evidence, to navigate evolving regulatory expectations for excipients, and to structure supply chains that are responsive to geopolitical and tariff-related risks. Firms that proactively invest in these capabilities will find cyclodextrins an increasingly valuable tool in the formulation toolbox, particularly for complex APIs and delivery modalities that demand both scientific precision and operational reliability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cyclodextrin in Pharma Market, by Product Type

  • 8.1. Modified
    • 8.1.1. Hydroxypropyl Beta
    • 8.1.2. Methyl Beta
    • 8.1.3. Sulfobutyl Ether Beta
  • 8.2. Natural
    • 8.2.1. Alpha
    • 8.2.2. Beta
    • 8.2.3. Gamma

9. Cyclodextrin in Pharma Market, by Route Of Administration

  • 9.1. Nasal
    • 9.1.1. Drops
    • 9.1.2. Sprays
  • 9.2. Ophthalmic
  • 9.3. Oral
    • 9.3.1. Liquid
      • 9.3.1.1. Suspensions
      • 9.3.1.2. Syrups
    • 9.3.2. Solid
      • 9.3.2.1. Capsules
      • 9.3.2.2. Powders
      • 9.3.2.3. Tablets
  • 9.4. Parenteral
    • 9.4.1. Intramuscular
    • 9.4.2. Intravenous
  • 9.5. Topical
    • 9.5.1. Creams
    • 9.5.2. Gels
    • 9.5.3. Ointments

10. Cyclodextrin in Pharma Market, by Therapeutic Area

  • 10.1. Cardiovascular
    • 10.1.1. Antihypertensive Agents
    • 10.1.2. Lipid Lowering Agents
  • 10.2. Central Nervous System
    • 10.2.1. Antidepressants
    • 10.2.2. Neuroprotective Agents
  • 10.3. Infectious Diseases
    • 10.3.1. Antibiotic Agents
    • 10.3.2. Antiviral Agents
  • 10.4. Oncology
    • 10.4.1. Chemotherapeutic Agents
    • 10.4.2. Immunotherapy Agents

11. Cyclodextrin in Pharma Market, by Application

  • 11.1. Drug Delivery System
    • 11.1.1. Controlled Release
      • 11.1.1.1. Extended Release
      • 11.1.1.2. Sustained Release
    • 11.1.2. Targeted Delivery
  • 11.2. Solubility Enhancement
  • 11.3. Stability Improvement
  • 11.4. Taste Masking

12. Cyclodextrin in Pharma Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cyclodextrin in Pharma Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cyclodextrin in Pharma Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cyclodextrin in Pharma Market

16. China Cyclodextrin in Pharma Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Ashland Global Holdings Inc
  • 17.6. BASF SE
  • 17.7. Caldic B.V.
  • 17.8. Cargill Incorporated
  • 17.9. Cerbios-Pharma SA
  • 17.10. CycloChem Technologies Pvt. Ltd.
  • 17.11. CycloLab Ltd.
  • 17.12. Daicel Corporation
  • 17.13. Hebei Tianxu Biotechnology Co Ltd
  • 17.14. Hubei Guangji Pharmaceutical Co Ltd
  • 17.15. Jiangsu Zhiyuan Biotechnology Co Ltd
  • 17.16. Kleptose
  • 17.17. Kuraray Co Ltd
  • 17.18. Ligand Pharmaceuticals Incorporated
  • 17.19. Merck KGaA
  • 17.20. Nihon Shokuhin Kako Co Ltd
  • 17.21. Roquette Freres
  • 17.22. Samyang Corporation
  • 17.23. Shandong Binzhou Zhiyuan Biotechnology Co Ltd
  • 17.24. Shandong Tianli Pharmaceutical Co Ltd
  • 17.25. Shandong Xinda Biotechnology Co Ltd
  • 17.26. Shandong Yunzhou Biotechnology Co Ltd
  • 17.27. Shijiazhuang Hongwei Biotechnology Co Ltd
  • 17.28. Sichuan Kelong Chemical Co Ltd
  • 17.29. Tokyo Chemical Industry Co., Ltd.
  • 17.30. Wacker Chemie AG
  • 17.31. Wuhan Sinobiological Technology Co Ltd
  • 17.32. Zhejiang Huakang Pharmaceutical Co Ltd
  • 17.33. Zibo Qianhui Biological Technology Co Ltd
  • 17.34. Zibo Shuangfeng Chemical Co Ltd
  • 17.35. Zibo Zhenhua Chemical Co Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CYCLODEXTRIN IN PHARMA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CYCLODEXTRIN IN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CYCLODEXTRIN IN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY HYDROXYPROPYL BETA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY HYDROXYPROPYL BETA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY HYDROXYPROPYL BETA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY METHYL BETA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY METHYL BETA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY METHYL BETA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SULFOBUTYL ETHER BETA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SULFOBUTYL ETHER BETA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SULFOBUTYL ETHER BETA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ALPHA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ALPHA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ALPHA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY BETA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY BETA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY BETA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GAMMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GAMMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GAMMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SYRUPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SYRUPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SYRUPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIHYPERTENSIVE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIHYPERTENSIVE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIHYPERTENSIVE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIPID LOWERING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIPID LOWERING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIPID LOWERING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NEUROPROTECTIVE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NEUROPROTECTIVE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NEUROPROTECTIVE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIBIOTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIBIOTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIBIOTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIVIRAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIVIRAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIVIRAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUSTAINED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUSTAINED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TARGETED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TARGETED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLUBILITY ENHANCEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLUBILITY ENHANCEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLUBILITY ENHANCEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY STABILITY IMPROVEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY STABILITY IMPROVEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY STABILITY IMPROVEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TASTE MASKING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TASTE MASKING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TASTE MASKING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 314. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 315. ASEAN CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. ASEAN CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. ASEAN CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 318. ASEAN CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 319. ASEAN CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. ASEAN CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 321. ASEAN CYCLODEX